Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Equity Income: 2017-2021

Historic Equity Income for Theravance Biopharma (TBPH) over the last 5 years, with Dec 2021 value amounting to $104.0 million.

  • Theravance Biopharma's Equity Income rose 28.28% to $28.1 million in Q2 2022 from the same period last year, while for Jun 2022 it was $118.8 million, marking a year-over-year increase of 64.90%. This contributed to the annual value of $104.0 million for FY2021, which is 51.94% up from last year.
  • As of FY2021, Theravance Biopharma's Equity Income stood at $104.0 million, which was up 51.94% from $68.4 million recorded in FY2020.
  • Theravance Biopharma's Equity Income's 5-year high stood at $104.0 million during FY2021, with a 5-year trough of $170,000 in FY2017.
  • Over the past 3 years, Theravance Biopharma's median Equity Income value was $68.4 million (recorded in 2020), while the average stood at $68.7 million.
  • Data for Theravance Biopharma's Equity Income shows a peak YoY spiked of 6,477.65% (in 2018) over the last 5 years.
  • Over the past 5 years, Theravance Biopharma's Equity Income (Yearly) stood at $170,000 in 2017, then spiked by 6,477.65% to $11.2 million in 2018, then soared by 201.42% to $33.7 million in 2019, then spiked by 103.05% to $68.4 million in 2020, then spiked by 51.94% to $104.0 million in 2021.